Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan;44(1):E4-E5.
doi: 10.3174/ajnr.A7702. Epub 2022 Dec 8.

MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?

P F Høilund-Carlsen  1 , A Alavi  2 , G Perry  3 , J R Barrio  4
Affiliations
Comment

MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?

P F Høilund-Carlsen et al. AJNR Am J Neuroradiol. 2023 Jan.
No abstract available

PubMed Disclaimer

Comment in

  • Reply.
    Cogswell PM, Jack CR Jr, Barakos JA, Barkhof F, Benzinger TS, Raji CA, Poussaint TY, Ramanan VK, Whitlow CT. Cogswell PM, et al. AJNR Am J Neuroradiol. 2023 Jan;44(1):E6. doi: 10.3174/ajnr.A7731. Epub 2022 Dec 8. AJNR Am J Neuroradiol. 2023. PMID: 36574316 Free PMC article. No abstract available.

Comment on

References

    1. Cogswell PM, Barakos JA, Barkhof F, et al. . Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol 2022;43:E19–35 10.3174/ajnr.A7586 - DOI - PMC - PubMed
    1. Sevigny J, Chiao P, Bussière T, et al. . The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537:50–56 10.1038/nature19323 - DOI - PubMed
    1. Klein G, Delmar P, Voyle N, et al. . Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimers Res Ther 2019;11:101 10.1186/s13195-019-0559-z - DOI - PMC - PubMed
    1. Høilund-Carlsen PF, Alavi A. Aducanumab (marketed as Aduhelm) approval is likely based on misinterpretation of PET imaging data. J Alzheimers Dis 2021;84:1457–60 10.3233/JAD-215275 - DOI - PubMed